Literature DB >> 22461648

KRAS mutational status of endoscopic biopsies matches resection specimens.

Qing-Hua Yang1, Jason Schmidt, Genvieve Soucy, Robert Odze, Liza Dejesa-Jamanila, Keely Arnold, Christine Kuslich, Richard Lash.   

Abstract

AIMS: This study was performed to determine systematically whether KRAS mutational analysis in biopsy tissue is a reliable indicator of KRAS status in subsequent corresponding resection specimens.
METHODS: 30 colorectal cancer (CRC) patients with biopsy and corresponding subsequent surgical resection specimens were studied. KRAS mutational analysis was performed on each biopsy sample as well as two separate samples from each resection specimen by PCR and Sanger sequencing.
RESULTS: Overall, KRAS mutations were identified in 12/30 (40%) of the tumours. There was 100% correlation between biopsy and resection specimens regarding the presence or absence of KRAS mutations. In fact, the same point mutation was identified in both biopsy and corresponding resection specimens in 12/12 (100%) cases. In addition, in two cases, there were two different point mutations detected within the same biopsy specimen.
CONCLUSION: This study shows perfect correlation between KRAS mutation status in biopsy and resection specimens from an individual patient, and suggests that biopsy material is adequate for KRAS mutational analysis in CRC patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22461648     DOI: 10.1136/jclinpath-2012-200746

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  2 in total

1.  Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist's perspective.

Authors:  Umberto Malapelle; Claudio Bellevicine; Maria Salatiello; Caterina de Luca; Elisabetta Rispo; Palmira Riccio; Lucianna Sparano; Alfonso De Stefano; Chiara Carlomagno; Francesco Maria Maiello; Giulia Vita; Oscar Nappi; Giancarlo Troncone
Journal:  J Clin Pathol       Date:  2012-08-07       Impact factor: 3.411

2.  RAS mutations vary between lesions in synchronous primary colorectal cancer: testing only one lesion is not sufficient to guide anti-EGFR treatment decisions.

Authors:  Mariana Petaccia de Macedo; Fernanda Machado de Melo; Júlia da Silva Ribeiro; Celso Abdon Lopes de Mello; Maria Dirlei Ferreira de Souza Begnami; Fernando Augusto Soares; Dirce Maria Carraro; Isabela Werneck da Cunha
Journal:  Oncoscience       Date:  2015-02-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.